| Type | Sym | Class | Transaction | Value $ | Shares | Change % | Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | RGEN | Common Stock | Award | $0 | +8.69 K | +61.49% | $0.00 | 22.8 K | Feb 27, 2024 | Direct | F1 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | RGEN | Stock Option (Right to Buy) | Award | $0 | +8.63 K | $0.00 | 8.63 K | Feb 27, 2024 | Common Stock | 8.63 K | $192.71 | Direct | F2 |
| Id | Content |
|---|---|
| F1 | Mr. Bylund was awarded 8,691 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. |
| F2 | One third of the stock options will vest and become exercisable annually on February 27, 2025, February 27, 2026 and February 27, 2027. |